These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 2879464)

  • 1. Tertatolol does not affect biochemical markers of atherosclerosis in normo- and hyperlipidemic hypertensive patients.
    Richard JL; Martin C; Jacotot B
    Am J Nephrol; 1986; 6 Suppl 2():100-5. PubMed ID: 2879464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of tertatolol on atherogenicity indices in normo- or dis-lipemic hypertensive patients].
    Richard JL; Jacotot B
    Ann Med Interne (Paris); 1987; 138 Suppl 1():35-8. PubMed ID: 2884915
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of tertatolol in hypertensive patients with chronic renal failure.
    Beaufils M; Lantz B; Paillard F; Richet G
    Am J Nephrol; 1986; 6 Suppl 2():50-4. PubMed ID: 2879474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive and renal effects of tertatolol, a new beta-blocking agent, in hypertensive patients.
    Salvetti A; Leonetti G; Bernini GP; Rupoli L; Lucarini AR; Sangiorgio P; Mauro M; Di Stratis P; Zanchetti A
    Am J Nephrol; 1986; 6 Suppl 2():45-9. PubMed ID: 2879473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of tertatolol on lipid profile.
    Diehm C; Jacobsen O; Amendt K
    Cardiology; 1993; 83 Suppl 1():32-40. PubMed ID: 7903213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive effects of tertatolol: 3-month comparative study against acebutolol.
    Gallet M; Kleinknecht D; Maurice P
    Am J Nephrol; 1986; 6 Suppl 2():83-7. PubMed ID: 2879477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive effects of tertatolol. A comparative study versus atenolol.
    Mota JC; Carrageta MD; Felix S; Nunes AM; Jobbé-Duval M
    Am J Hypertens; 1989 Nov; 2(11 Pt 2):284S-288S. PubMed ID: 2573377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal hemodynamic effects of tertatolol in essential hypertension.
    Paillard F; Lantz B; Leviel F; Ardaillou R
    Am J Nephrol; 1986; 6 Suppl 2():40-4. PubMed ID: 2879472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Renal effects of intravenous tertatolol in essential arterial hypertension].
    Chaignon M; Brouard R; Lucsko M; Guédon J
    Arch Mal Coeur Vaiss; 1990 Jul; 83(8):1219-22. PubMed ID: 1979729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles.
    Yoo WH
    J Rheumatol; 2004 Sep; 31(9):1746-53. PubMed ID: 15338494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereospecificity of beta-adrenoceptor blockade and renal vasodilatation by tertatolol.
    Smits JF; Zeegers HH; Struyker-Boudier HA
    Arch Int Pharmacodyn Ther; 1989; 298():164-71. PubMed ID: 2569294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity.
    Kirch W; Milferstädt S; Halabi A; Rocher I; Efthymiopoulos C; Jung L
    Cardiovasc Drugs Ther; 1990 Apr; 4(2):487-91. PubMed ID: 1981019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of bucindolol on plasma HDL cholesterol subfractions and other plasma lipids in essential hypertensive patients.
    Lehtonen A; Tanskanen A; Temmerman J
    Int J Clin Pharmacol Ther Toxicol; 1987 Aug; 25(8):448-51. PubMed ID: 2888737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of beta blockers with intrinsic sympathomimetic activity on blood pressure and blood lipids in patients with essential hypertension].
    Serro-Azul JB; Wajngarten M; Santomauro A; Braga A; Yazbek Júnior P; Bellotti G; Serro-Azul LG; Pileggi F
    Arq Bras Cardiol; 1989 Dec; 53(6):321-5. PubMed ID: 2700113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular response to adrenergic stimulation during treatment with tertatolol. A new non-cardioselective beta-blocking agent in primary hypertensive patients.
    Fasano ML; Gaeta I; De Simone G; Iannuzzi R; Ferrara LA
    Jpn Heart J; 1991 Jul; 32(4):435-44. PubMed ID: 1683411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of clinical safety and efficacy of tertatolol.
    Vivet P
    Cardiology; 1993; 83 Suppl 1():41-50. PubMed ID: 7903214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pindolol and metoprolol on plasma lipids and lipoproteins.
    Pasotti C; Capra A; Fiorella G; Vibelli C; Chierichetti SM
    Br J Clin Pharmacol; 1982; 13(Suppl 2):435S-439S. PubMed ID: 7104157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tertatolol potentiates exercise-induced atrial natriuretic peptide release by increasing atrial diameter in healthy subjects.
    Berlin I; Deray G; Lechat P; Maistre G; Landault C; Chermat V; Brouard R; Ressayre C; Puech AJ
    Cardiology; 1993; 83 Suppl 1():16-24. PubMed ID: 7903211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-adrenergic receptor changes during tertatolol treatment in healthy volunteers: relevance for beta-blocking therapy.
    De Blasi A; Lipartiti M; Garattini S
    Am J Nephrol; 1986; 6 Suppl 2():69-73. PubMed ID: 2879475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension.
    Sasaki J; Kajiyama G; Kusukawa R; Mori H; Koga S; Takagi R; Tanaka N; Ogawa N; Arakawa K
    Int J Clin Pharmacol Ther; 1994 Dec; 32(12):660-4. PubMed ID: 7881705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.